Lv2
158 积分 2025-06-04 加入
The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond
3天前
已完结
Contemporary design of small-molecule kinase modulators: orthosteric, allosteric and induced-proximity strategies
3天前
已完结
The ovarian cancer drug market
3天前
已关闭
Safety considerations for cereblon-recruiting targeted protein degraders
3天前
已完结
Early Process Development of a Heterobifunctional Protein Degrader
5天前
已完结
Selective and Potent Molecular Glue Degraders for NIMA‐Related Kinase 7
16天前
已完结
Discovery of Naphthyridinone Derivatives as Selective PKMYT1/WEE1 Dual Inhibitors for Cancer Therapy
23天前
已完结
Discovery and Optimization of Orally Bioavailable Heterobifunctional Degraders of KAT2A/B for the Treatment of Cancer
27天前
已完结
From KRASG12D to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
1个月前
已完结
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization towards orally available bifunctional protein degraders
1个月前
已完结
皖公网安备34019202002308
